Freedom-2 Holdings, Inc. Announces $5.4 Million in Series B Funding

CHERRY HILL, N.J.--(BUSINESS WIRE)--Freedom-2 Holdings, Inc., parent of Freedom-2, Inc., developers of Infinitink, the permanent but more easily removable tattoo ink, today announced that it has secured $5.4 million in Series B Convertible Preferred financing led by new and current independent investors.

“This second round of financing rewards our ability to achieve company goals”

This rights offering subscribed to by institutions and individual investors provides Freedom-2 with the ability to move from the research and development stage to product commercialization. The financing will be used to complete the purchase of an operating facility in Cherry Hill, NJ, hire additional staff, launch the retail product plus continue development of the company’s palette of color inks.

“This second round of financing rewards our ability to achieve company goals,” said Martin Schmieg, CEO of Freedom-2, Inc. “It also demonstrates our current investors’ confidence as they bring additional investors to Freedom-2 as we prepare to deliver products to market.”

Recently recognized as one of “The Best Inventions of the Year” by Time Magazine, Freedom-2’s Infinitink technology is the first permanent tattoo ink engineered specifically for improved removability. F2 uses bioabsorbable pigments and dyes that are encapsulated in a biocompatible polymer forming a microencapsulated colored bead. These beads are used to make the ink. Tattoo artists use traditional delivery methods to provide a Freedom-2 Infinitink tattoo – the only difference is the ink. An Infinitink tattoo is easily removed using traditional laser therapy that breaks the polymer beads allowing the body to naturally absorb the pigments trapped inside.

About Freedom-2, Inc.

Founded in 1999, Freedom-2, Inc., is the first company to engineer and patent a permanent, but more easily removable ink for tattoos and permanent cosmetics. The Freedom-2 ink technology was co-discovered by R. Rox Anderson, M.D., Wellman Center for Photomedicine at the Massachusetts General Hospital, Craig A. Drill, Susanna Mlynarczyk-Evans, Ph.D., UC-San Francisco, Bruce Klitzman, Ph.D. and Kim Edward Koger, M.D., F.A.C.S., of Duke University. Freedom-2, Inc. is a privately held company with initial funding from private investors, institutional investment firms and private investment vehicles. For more general information about the company log onto www.freedom2ink.com.

Safe Harbor Statement

Some of the statements included in this presentation are forward-looking statements that involve a number of risks and uncertainties, including, but not limited to, statements regarding future market opportunity and future financial performance. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.